title: The effects of methylprednisolone on complement, immunoglobulins and pulmonary neutrophil sequestration during cardiopulmonary bypass.
abstract: In this study, the authors administered high dose (30 mg/kg body weight i.v.) methylprednisolone before cardiopulmonary bypass to observe the effects on complement, immunoglobulins and pulmonary neutrophil sequestration. Fifty patients undergoing valve replacements were included in this study. Patients were divided into two groups: group I (20 patients) served as control and did not receive methylprednisolone, group II (30 patients) received methylprednisolone. Blood samples for complements (C3c and C4) were taken, before cardiopulmonary bypass, at 5, 10 and 30 min intervals from the end of cardiopulmonary bypass, after reversal of heparin with protamine infusion, and after skin closure. Blood samples for immunoglobulins were taken before cardiopulmonary bypass, 30 min after onset of cardiopulmonary bypass and after skin closure. After onset of cardiopulmonary bypass, all C3c and C4 levels decreased in both groups. There was a significant decrease in C4 levels at end of cardiopulmonary bypass and after protamine infusion in group I compared with group II (P < 0.05). C3c levels in group I decreased significantly compared with group II after 30 min of cardiopulmonary bypass and after protamine infusion (P < 0.05). All immunoglobulin (IgG, IgM, IgA) levels were decreased in both groups, but the decrease in IgG was statistically significant after skin closure in group I compared with group II (P < 0.05). Pulmonary neutrophil sequestration was higher in the control group compared with the methyl-prednisolone group (P < 0.05). In conclusion, methylprednisolone administration before cardiopulmonary bypass may prevent the harmful effects of complement activation, immunoglobulin denaturation and neutrophil sequestration in the pulmonary capillary system.
authors.affiliation: Department of Cardiovascular Surgery, Osmangazi University, Faculty of Medicine, Eskişehir, Turkey.
authors.forename: S
authors.initials: S
authors.lastname: Dernek
authors.forename: B
authors.initials: B
authors.lastname: Tünerir
authors.forename: B
authors.initials: B
authors.lastname: Sevin
authors.forename: R
authors.initials: R
authors.lastname: Aslan
authors.forename: O
authors.initials: O
authors.lastname: Uyguç
authors.forename: T
authors.initials: T
authors.lastname: Kural
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001021:Aortic Valve / Q000601:surgery*; D001998:Bronchopulmonary Sequestration; D002315:Cardiopulmonary Bypass / Q000379:methods*; D003167:Complement Activation / Q000187:drug effects*; D003176:Complement C3 / Q000187:drug effects; D003181:Complement C4 / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000175:diagnosis / Q000601:surgery; D006801:Humans; D007136:Immunoglobulins / Q000187:drug effects; D007275:Injections, Intravenous; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D009504:Neutrophils / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication; D012016:Reference Values; D012214:Rheumatic Heart Disease / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D003176:Complement C3; D003181:Complement C4; D007136:Immunoglobulins; D008775:Methylprednisolone